Compare MWC & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MWC | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 78.9M |
| IPO Year | 2025 | 2023 |
| Metric | MWC | NRXS |
|---|---|---|
| Price | $1.77 | $5.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 159.9K | 58.4K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.78 | $2.21 |
| 52 Week High | $4.20 | $9.33 |
| Indicator | MWC | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 33.39 |
| Support Level | $1.33 | $5.50 |
| Resistance Level | $1.62 | $7.37 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 20.51 | 35.33 |
Micware Co Ltd is a Japan-based provider of software development services and inventive information technology (IT) solutions mainly focused on the automotive and mobility sectors. Its main focus is the development and sale of in-vehicle infotainment (IVI) systems that cover a broad range of modern car functionality from multimedia to navigation, human-machine interface, telematics, and driver assistance. The Group is also engaged in the development of navigation software and location information-based smartphone applications. Its reportable operating segments are: SDV (software-defined vehicles), LBS (location-based service), and Other. Maximum revenue is generated from the SDV segment. Geographically, the Group derives maximum revenue from Japan and the rest from international markets.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).